Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Thursday, May 5, 2011

Company Profile for Stem Cell Stock, Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG)

POINT ROBERTS, Wash., May 5, 2011 - www.InvestorIdeas.com, a leader in investor research including biotech and stem cell stocks, issues the company profile for stem cell company, Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) for investors following the sector.
About Vitro Diagnostics, Inc. (OTCQB: VODG)
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.
Recent News;
Stem Cell Stock Vitro (OTCQB: VODG) Announces Progress in the Achievement of Profitability
Revenue Increase Due to Licensing Fertility Drug Patents, Products and Technology
GOLDEN, Colo. - May 3, 2011 (Investorideas.com Newswire) - Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced progress and achievement of key financial goals in the transformation of the Company from a research operation to a profitable commercial operation with sustained earnings growth. Income was recently increased by $200,000 through license fees obtained by licensing our fertility drug patents, products and technology. This infertility treatment technology was developed previously and is no longer a primary operational goal as the Company is now focused on commercialization of stem cell products and technology. Thus, the recent license of this intellectual property allows the Company to monetize previously written-off assets through income from license fees and potential sales royalties while also pursuing additional product revenues through sales of its stem cell products.
Full News: http://www.investorideas.com/CO/VODG/news/2011/05031.asp
More info:
Visit the VODG company profile on Investorideas.com  
Visit the Biotech stocks directory at Investorideas.com
Request news and info on VODG
Sign up for the free investor news letter and get stock alerts in leading sectors!
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: VODG is a paid showcase stem cell stock on Investorideas.com (one month $1000)
www.InvestorIdeas.com/About/Disclaimer.asp
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

No comments:

Post a Comment